purchase customization

1 IBS-C Drugs Market Overview
1.1 Product Overview and Scope of IBS-C Drugs
1.2 IBS-C Drugs Segment by Type
1.2.1 Global IBS-C Drugs Sales Growth Rate Comparison by Type (2023-2030)
1.2.2 Linaclotide
1.2.3 Lubiprostone
1.2.4 Osmotic Laxatives
1.2.5 Stimulant Laxatives
1.2.6 Others
1.3 IBS-C Drugs Segment by Application
1.3.1 Global IBS-C Drugs Sales Comparison by Application: (2023-2030)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global IBS-C Drugs Market Size Estimates and Forecasts
1.4.1 Global IBS-C Drugs Revenue 2017-2030
1.4.2 Global IBS-C Drugs Sales 2017-2030
1.4.3 IBS-C Drugs Market Size by Region: 2017 Versus 2021 Versus 2030
2 IBS-C Drugs Market Competition by Manufacturers
2.1 Global IBS-C Drugs Sales Market Share by Manufacturers (2017-2023)
2.2 Global IBS-C Drugs Revenue Market Share by Manufacturers (2017-2023)
2.3 Global IBS-C Drugs Average Price by Manufacturers (2017-2023)
2.4 Manufacturers IBS-C Drugs Manufacturing Sites, Area Served, Product Type
2.5 IBS-C Drugs Market Competitive Situation and Trends
2.5.1 IBS-C Drugs Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest IBS-C Drugs Players Market Share by Revenue
2.5.3 Global IBS-C Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 IBS-C Drugs Retrospective Market Scenario by Region
3.1 Global IBS-C Drugs Retrospective Market Scenario in Sales by Region: 2017-2023
3.2 Global IBS-C Drugs Retrospective Market Scenario in Revenue by Region: 2017-2023
3.3 North America IBS-C Drugs Market Facts & Figures by Country
3.3.1 North America IBS-C Drugs Sales by Country
3.3.2 North America IBS-C Drugs Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe IBS-C Drugs Market Facts & Figures by Country
3.4.1 Europe IBS-C Drugs Sales by Country
3.4.2 Europe IBS-C Drugs Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific IBS-C Drugs Market Facts & Figures by Region
3.5.1 Asia Pacific IBS-C Drugs Sales by Region
3.5.2 Asia Pacific IBS-C Drugs Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America IBS-C Drugs Market Facts & Figures by Country
3.6.1 Latin America IBS-C Drugs Sales by Country
3.6.2 Latin America IBS-C Drugs Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa IBS-C Drugs Market Facts & Figures by Country
3.7.1 Middle East and Africa IBS-C Drugs Sales by Country
3.7.2 Middle East and Africa IBS-C Drugs Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global IBS-C Drugs Historic Market Analysis by Type
4.1 Global IBS-C Drugs Sales Market Share by Type (2017-2023)
4.2 Global IBS-C Drugs Revenue Market Share by Type (2017-2023)
4.3 Global IBS-C Drugs Price by Type (2017-2023)
5 Global IBS-C Drugs Historic Market Analysis by Application
5.1 Global IBS-C Drugs Sales Market Share by Application (2017-2023)
5.2 Global IBS-C Drugs Revenue Market Share by Application (2017-2023)
5.3 Global IBS-C Drugs Price by Application (2017-2023)
6 Key Companies Profiled
6.1 Catalent Pharmaceuticals Solutions
6.1.1 Catalent Pharmaceuticals Solutions Corporation Information
6.1.2 Catalent Pharmaceuticals Solutions Description and Business Overview
6.1.3 Catalent Pharmaceuticals Solutions IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.1.4 Catalent Pharmaceuticals Solutions IBS-C Drugs Product Portfolio
6.1.5 Catalent Pharmaceuticals Solutions Recent Developments/Updates
6.2 Nestle
6.2.1 Nestle Corporation Information
6.2.2 Nestle Description and Business Overview
6.2.3 Nestle IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.2.4 Nestle IBS-C Drugs Product Portfolio
6.2.5 Nestle Recent Developments/Updates
6.3 Abbott Laboratories
6.3.1 Abbott Laboratories Corporation Information
6.3.2 Abbott Laboratories Description and Business Overview
6.3.3 Abbott Laboratories IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.3.4 Abbott Laboratories IBS-C Drugs Product Portfolio
6.3.5 Abbott Laboratories Recent Developments/Updates
6.4 Synergy Pharmaceuticals
6.4.1 Synergy Pharmaceuticals Corporation Information
6.4.2 Synergy Pharmaceuticals Description and Business Overview
6.4.3 Synergy Pharmaceuticals IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.4.4 Synergy Pharmaceuticals IBS-C Drugs Product Portfolio
6.4.5 Synergy Pharmaceuticals Recent Developments/Updates
6.5 Sucampo Pharmaceuticals
6.5.1 Sucampo Pharmaceuticals Corporation Information
6.5.2 Sucampo Pharmaceuticals Description and Business Overview
6.5.3 Sucampo Pharmaceuticals IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.5.4 Sucampo Pharmaceuticals IBS-C Drugs Product Portfolio
6.5.5 Sucampo Pharmaceuticals Recent Developments/Updates
6.6 Novartis Pharma Ag
6.6.1 Novartis Pharma Ag Corporation Information
6.6.2 Novartis Pharma Ag Description and Business Overview
6.6.3 Novartis Pharma Ag IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.6.4 Novartis Pharma Ag IBS-C Drugs Product Portfolio
6.6.5 Novartis Pharma Ag Recent Developments/Updates
6.7 Astellas Pharmaceuticals
6.6.1 Astellas Pharmaceuticals Corporation Information
6.6.2 Astellas Pharmaceuticals Description and Business Overview
6.6.3 Astellas Pharmaceuticals IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.4.4 Astellas Pharmaceuticals IBS-C Drugs Product Portfolio
6.7.5 Astellas Pharmaceuticals Recent Developments/Updates
6.8 Ardelyx, Inc
6.8.1 Ardelyx, Inc Corporation Information
6.8.2 Ardelyx, Inc Description and Business Overview
6.8.3 Ardelyx, Inc IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.8.4 Ardelyx, Inc IBS-C Drugs Product Portfolio
6.8.5 Ardelyx, Inc Recent Developments/Updates
6.9 Synthetic Biologics, Inc
6.9.1 Synthetic Biologics, Inc Corporation Information
6.9.2 Synthetic Biologics, Inc Description and Business Overview
6.9.3 Synthetic Biologics, Inc IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.9.4 Synthetic Biologics, Inc IBS-C Drugs Product Portfolio
6.9.5 Synthetic Biologics, Inc Recent Developments/Updates
6.10 Teva Pharmaceutical Industries
6.10.1 Teva Pharmaceutical Industries Corporation Information
6.10.2 Teva Pharmaceutical Industries Description and Business Overview
6.10.3 Teva Pharmaceutical Industries IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.10.4 Teva Pharmaceutical Industries IBS-C Drugs Product Portfolio
6.10.5 Teva Pharmaceutical Industries Recent Developments/Updates
6.11 Bama-Geve, SLU
6.11.1 Bama-Geve, SLU Corporation Information
6.11.2 Bama-Geve, SLU IBS-C Drugs Description and Business Overview
6.11.3 Bama-Geve, SLU IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.11.4 Bama-Geve, SLU IBS-C Drugs Product Portfolio
6.11.5 Bama-Geve, SLU Recent Developments/Updates
6.12 Ferring BV
6.12.1 Ferring BV Corporation Information
6.12.2 Ferring BV IBS-C Drugs Description and Business Overview
6.12.3 Ferring BV IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.12.4 Ferring BV IBS-C Drugs Product Portfolio
6.12.5 Ferring BV Recent Developments/Updates
6.13 Ironwood Pharmaceuticals, Inc
6.13.1 Ironwood Pharmaceuticals, Inc Corporation Information
6.13.2 Ironwood Pharmaceuticals, Inc IBS-C Drugs Description and Business Overview
6.13.3 Ironwood Pharmaceuticals, Inc IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.13.4 Ironwood Pharmaceuticals, Inc IBS-C Drugs Product Portfolio
6.13.5 Ironwood Pharmaceuticals, Inc Recent Developments/Updates
6.14 Salix Pharmaceuticals Ltd
6.14.1 Salix Pharmaceuticals Ltd Corporation Information
6.14.2 Salix Pharmaceuticals Ltd IBS-C Drugs Description and Business Overview
6.14.3 Salix Pharmaceuticals Ltd IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.14.4 Salix Pharmaceuticals Ltd IBS-C Drugs Product Portfolio
6.14.5 Salix Pharmaceuticals Ltd Recent Developments/Updates
6.15 Norgine B.V
6.15.1 Norgine B.V Corporation Information
6.15.2 Norgine B.V IBS-C Drugs Description and Business Overview
6.15.3 Norgine B.V IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.15.4 Norgine B.V IBS-C Drugs Product Portfolio
6.15.5 Norgine B.V Recent Developments/Updates
6.16 Prometheus Laboratories Inc
6.16.1 Prometheus Laboratories Inc Corporation Information
6.16.2 Prometheus Laboratories Inc IBS-C Drugs Description and Business Overview
6.16.3 Prometheus Laboratories Inc IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.16.4 Prometheus Laboratories Inc IBS-C Drugs Product Portfolio
6.16.5 Prometheus Laboratories Inc Recent Developments/Updates
6.17 Actavis Nordic A/S
6.17.1 Actavis Nordic A/S Corporation Information
6.17.2 Actavis Nordic A/S IBS-C Drugs Description and Business Overview
6.17.3 Actavis Nordic A/S IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.17.4 Actavis Nordic A/S IBS-C Drugs Product Portfolio
6.17.5 Actavis Nordic A/S Recent Developments/Updates
6.18 Albireo Pharma Inc
6.18.1 Albireo Pharma Inc Corporation Information
6.18.2 Albireo Pharma Inc IBS-C Drugs Description and Business Overview
6.18.3 Albireo Pharma Inc IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.18.4 Albireo Pharma Inc IBS-C Drugs Product Portfolio
6.18.5 Albireo Pharma Inc Recent Developments/Updates
6.19 Yuhan Corp
6.19.1 Yuhan Corp Corporation Information
6.19.2 Yuhan Corp IBS-C Drugs Description and Business Overview
6.19.3 Yuhan Corp IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.19.4 Yuhan Corp IBS-C Drugs Product Portfolio
6.19.5 Yuhan Corp Recent Developments/Updates
6.20 Astrazeneca Plc
6.20.1 Astrazeneca Plc Corporation Information
6.20.2 Astrazeneca Plc IBS-C Drugs Description and Business Overview
6.20.3 Astrazeneca Plc IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.20.4 Astrazeneca Plc IBS-C Drugs Product Portfolio
6.20.5 Astrazeneca Plc Recent Developments/Updates
6.21 The Menarini Group
6.21.1 The Menarini Group Corporation Information
6.21.2 The Menarini Group IBS-C Drugs Description and Business Overview
6.21.3 The Menarini Group IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.21.4 The Menarini Group IBS-C Drugs Product Portfolio
6.21.5 The Menarini Group Recent Developments/Updates
6.22 Ono Pharmaceutical Co., Ltd
6.22.1 Ono Pharmaceutical Co., Ltd Corporation Information
6.22.2 Ono Pharmaceutical Co., Ltd IBS-C Drugs Description and Business Overview
6.22.3 Ono Pharmaceutical Co., Ltd IBS-C Drugs Sales, Revenue and Gross Margin (2017-2023)
6.22.4 Ono Pharmaceutical Co., Ltd IBS-C Drugs Product Portfolio
6.22.5 Ono Pharmaceutical Co., Ltd Recent Developments/Updates
7 IBS-C Drugs Manufacturing Cost Analysis
7.1 IBS-C Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of IBS-C Drugs
7.4 IBS-C Drugs Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 IBS-C Drugs Distributors List
8.3 IBS-C Drugs Customers
9 IBS-C Drugs Market Dynamics
9.1 IBS-C Drugs Industry Trends
9.2 IBS-C Drugs Market Drivers
9.3 IBS-C Drugs Market Challenges
9.4 IBS-C Drugs Market Restraints
10 Global Market Forecast
10.1 IBS-C Drugs Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of IBS-C Drugs by Type (2023-2030)
10.1.2 Global Forecasted Revenue of IBS-C Drugs by Type (2023-2030)
10.2 IBS-C Drugs Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of IBS-C Drugs by Application (2023-2030)
10.2.2 Global Forecasted Revenue of IBS-C Drugs by Application (2023-2030)
10.3 IBS-C Drugs Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of IBS-C Drugs by Region (2023-2030)
10.3.2 Global Forecasted Revenue of IBS-C Drugs by Region (2023-2030)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer